I personally believe that many underestimate our c

I personally believe that many underestimate our combo by big numbers ...
.
About 190K patients MDR2 and MDR3 CCR5 positive ( as we usually say here ) only in USA..

Lets count 20% of them at the beginning in USA only,
for 35,000.00 doll / year is above 1.3 B doll.

This is IMO conservative , knowing Leronlimab well by now , I will put all my MDR2 , RS-HIV strain patients on Leronlimab , so they don't progress to MDR3 where patients are much sicker already ..
All doctors will be educated I am sure ...

Our competition is mostly Maraviroc , since Ibalizumab is only IV treatment for about 25,000 patients with MDR3.

And according to Dr NP , immediately they will apply for Europe , and Europe is twice as big , and approval should come very fast ...

And than Asia , Africa , South and Central America , where number of MDR2 and MDR3 patients is much higher..plus treatment for many patients much more reliable as once a week SC , and not daily tabl...

Also some patients will not be able to stay only on mono imo , this is why Dr Lalezari is saying , Combine Leronlimab with another once a week medicine , and it will be a " killer "

All imo.